Apotea AB (publ)CHIX:APOTES 18 Altman Z-Score is 8.20 as of Jul. 11, 2026, which is 7% below its 10-year median of 8.81. GuruFocus rates CHIX:APOTES with a GF Score™ of 18/100. The stock has 1 warning sign investors should review. Among 662 Healthcare Providers & Services companies, Apotea AB (publ) ranks better than 87.92% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 8.34 is strong.
Apotea AB (publ) has a Altman Z-Score of 8.20, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Apotea AB (publ)'s Altman Z-Score or its related term are showing as below:
CHIX:APOTEs'
s Altman Z-Score Range Over the Past 10 Years
Min: 7.64 Med: 8.81 Max: 10.48
Current: 8.34
During the past 5 years, Apotea AB (publ)'s highest Altman Z-Score was 10.48. The lowest was 7.64. And the median was 8.81.
Apotea AB (publ) (CHIX:APOTEs) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Apotea AB (publ) Altman Z-Score Related Terms
Apotea AB (publ) Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Apotea AB (publ)'s Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apotea AB (publ) Altman Z-Score Competitor Comparison
For the Pharmaceutical Retailers subindustry, Apotea AB (publ)'s Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apotea AB (publ) Altman Z-Score vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Apotea AB (publ)'s Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Apotea AB (publ)'s Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Apotea AB (publ)'s Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.1628
+
1.4
*
0.4106
+
3.3
*
0.14
+
0.6
*
6.0766
+
1.0
*
3.3263
=
8.20
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Apotea AB (publ) (CHIX:APOTES) has a Altman Z-Score of 8.20 as of Jul. 11, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Apotea AB (publ) and its competitors. This is near median its historical median of 8.81. Over the past decade, Apotea AB (publ)'s Altman Z-Score has ranged from 7.64 to 10.48. According to the industry distribution chart, Apotea AB (publ) ranks #80 out of 662 companies in the Healthcare Providers & Services industry, placing it in the top 12.1%.
Is Apotea AB (publ)'s Altman Z-Score too high?
Apotea AB (publ)'s current Altman Z-Score of 8.20 is near median its 10-year median of 8.81. Over the past 10 years, this metric has ranged from a low of 7.64 to a high of 10.48. The Healthcare Providers & Services industry median Altman Z-Score is 2.46. Apotea AB (publ)'s value of 8.20 is 233.3% above this industry median. Based on the distribution chart, Apotea AB (publ) ranks #80 out of 662 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Apotea AB (publ) has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Apotea AB (publ)'s Altman Z-Score compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Apotea AB (publ) ranks #80 out of 662 companies for Altman Z-Score. This places Apotea AB (publ) in the top 12% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.46. Apotea AB (publ)'s value of 8.20 is 233.3% above this benchmark. Historically, Apotea AB (publ)'s own Altman Z-Score has ranged from 7.64 to 10.48 over the past decade. While the company's 10-year median is 8.81 vs. the industry median of 2.46, Apotea AB (publ) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Healthcare Providers & Services company?
The median Altman Z-Score among Healthcare Providers & Services companies is 2.46, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apotea AB (publ)'s current Altman Z-Score of 8.20 is 233.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Apotea AB (publ) and its competitors. For the Healthcare Providers & Services industry, the median Altman Z-Score is 2.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apotea AB (publ)'s current Altman Z-Score is 8.20, which is near median its own 10-year median of 8.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apotea AB (publ) stock overvalued right now?
Apotea AB (publ) (CHIX:APOTES) has a current Altman Z-Score of 8.20. The current Altman Z-Score is 8.20, which is near median its 10-year median of 8.81 and 233.3% above the Healthcare Providers & Services industry median of 2.46. Apotea AB (publ)'s overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Apotea AB (publ) (CHIX:APOTES), the current Altman Z-Score is 8.20 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Apotea AB (publ) is engaged in the online pharmacy with fast deliveries, good prices and a large selection. Its vision is to be tomorrow's pharmacy by constantly facilitating and simplifying for the customer.
18GF Score
Get the complete analysis for CHIX:APOTES
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:APOTES has been successfully added to your 
